Publication:
Outcome of Epidermal Growth Factor Receptor Mutated and Non Mutated Adenocarcinoma Lung to Standard Therapy

creativeworkseries.issn1999-6217
dc.contributor.authorDulal, Soniya
dc.contributor.authorMishra, Akshat
dc.contributor.authorShah, Aarati
dc.contributor.authorAcharya, Bibek
dc.contributor.authorShilpakar, Ramila
dc.contributor.authorSandhya, Chapagain, Acharya
dc.contributor.authorKarn, Ambuj
dc.contributor.authorSharma, Rajeev
dc.contributor.authorGautam, Balram
dc.contributor.authorPaudel, Bishnu Dutta
dc.date.accessioned2025-07-30T07:56:31Z
dc.date.available2025-07-30T07:56:31Z
dc.date.issued2023
dc.descriptionSoniya Dulal B. P. Koirala Institute of Health Sciences, Dharan, Nepal Akshat Mishra B. P. Koirala Institute of Health Sciences, Dharan, Nepal Aarati Shah Medical Education Commission, Sanothimi, Bhaktapur, Nepal Bibek Acharya NAMS, Bir Hospital, Kathmandu, Nepal Ramila Shilpakar NAMS, Bir Hospital, Kathmandu, Nepal Sandhya Chapagain Acharya NAMS, Bir Hospital, Kathmandu, Nepal Ambuj Karn NAMS, Bir Hospital, Kathmandu, Nepal Rajeev Sharma B. P. Koirala Institute of Health Sciences, Dharan, Nepal Balram Gautam Decode Genomics and Research Center, Sinamangal, Nepal Bishnu Dutta Paudel Bhaktapur Cancer Hospital, Nepal
dc.description.abstractAbstract Background: Asian patients with adenocarcinoma of lung have higher incidence of epidermal growth factor receptor mutations which predict increased response and survival in patients to oral tyrosine kinase inhibitors. This study was conducted to study the frequency of epidermal growth factor receptor mutation in patients in Nepal and compare the outcome in epidermal growth factor receptor mutated versus non-mutated patients receiving standard therapy. Methods: This is an observational study conducted among newly diagnosed patients with stage IV adenocarcinoma of lung in Bir Hospital from April 2017 to June 2018. Demographic and clinical data collection along with epidermal growth factor receptor mutation testing was done. Patients with epidermal growth factor receptor mutations received Gefitinib while non-mutated patients received systemic chemotherapy. Response evaluation, progression free survival at 1 year, objective response rate and quality of life were compared. Follow up period was for 1 year. Results: Eighty three (33%, n=253) patients were diagnosed with adenocarcinoma of the lung with mean age at diagnosis being 59.4 years. epidermal growth factor receptor mutations were found in 29% patients. Complete response was achieved in 9.1% vs 3.0 % (p=0.46), objective response rate was 27.3% versus 15.2% (p=0.23), progression free survival at 1 year was 39% vs 27%, (p = 0.29) and mean score of global health status was 68.1 versus 61.6 in epidermal growth factor receptor mutated versus non-mutated (p = 0.036). Conclusions: The frequency of epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung was lower than in Eastern Asian studies, but higher than in western populations. epidermal growth factor receptor mutated patients had improved survival, better treatment response and quality of life in comparison with non-mutated. Keywords: Adenocarcinoma of lung; EGFR; quality of life
dc.identifierhttps://doi.org/10.33314/jnhrc.v21i02.4764
dc.identifier.urihttps://hdl.handle.net/20.500.14572/982
dc.language.isoen_US
dc.publisherNepal Health Research Council
dc.titleOutcome of Epidermal Growth Factor Receptor Mutated and Non Mutated Adenocarcinoma Lung to Standard Therapy
dc.typeArticle
dspace.entity.typePublication
local.article.typeOriginal Article
oaire.citation.endPage335
oaire.citation.startPage330
relation.isJournalIssueOfPublication3d469339-0e4d-4c21-a203-895a72cdfddc
relation.isJournalIssueOfPublication.latestForDiscovery3d469339-0e4d-4c21-a203-895a72cdfddc
relation.isJournalOfPublication40bd2739-8b19-447c-be60-723a1bdd1dcd

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
330-335.pdf
Size:
282.95 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed to upon submission
Description:

Collections